



(51) International Patent Classification:

C07D 213/40 (2006.01) A61P 1/00 (2006.01)
C07D 213/82 (2006.01) A61P 17/06 (2006.01)
C07D 401/12 (2006.01) A61P 25/14 (2006.01)
C07D 405/12 (2006.01) A61P 25/16 (2006.01)
C07D 413/10 (2006.01) A61P 25/18 (2006.01)
C07D 413/14 (2006.01) A61P 25/28 (2006.01)
C07D 413/12 (2006.01) A61P 25/34 (2006.01)
A61K 31/44 (2006.01)

(21) International Application Number:

PCT/EP2012/053047

(22) International Filing Date:

23 February 2012 (23.02.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

11155937.3 25 February 2011 (25.02.2011) EP

(71) Applicant (for all designated States except US):
JANSSEN PHARMACEUTICA NV [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **DE BOECK, Benoît, Christian, Albert, Ghislain** [BE/BE]; c/o Janssen Pharmaceutica NV, Turnhoutseweg 30, B-2340 Beerse (BE). **ROMBOUTS, Geert** [BE/BE]; c/o Janssen Pharmaceutica NV, Turnhoutseweg 30, B-2340 Beerse (BE). **LEEN-AERTS, Joseph, Elisabeth** [BE/BE]; c/o Janssen Pharmaceutica NV, Turnhoutseweg 30, B-2340 Beerse (BE). **MACDONALD, Gregor, James** [GB/BE]; c/o Janssen Pharmaceutica NV, Turnhoutseweg 30, B-2340 Beerse (BE).

(74) Common Representative: JANSSEN PHARMACEUTICA NV; Turnhoutseweg 30, B-2340 Beerse (BE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(88) Date of publication of the international search report:

18 October 2012

(54) Title: (PYRIDIN-4-YL)BENZYLAMIDES AS ALLOSTERIC MODULATORS OF ALPHA 7 nAChR

(57) Abstract: The present invention relates to (pyridin-4-yl)benzylamides derivatives and pharmaceutically acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy. The invention particularly relates to positive allosteric modulators of nicotinic acetylcholine receptors, such positive allosteric modulators having the capability to increase the efficacy of nicotinic receptor agonists.

